StopBleed by Miraqules: India’s homegrown innovation to save lives instantly

In a country where road accidents claim nearly 700 lives a day—and excessive blood loss is often the cause—an emergency hemostat could mean the difference between life and death. Miraqules, a medtech startup, has developed StopBleed, a novel nano-biopolymer solution designed to control bleeding rapidly and effectively. The product, first conceptualized as a master’s thesis, is now the centerpiece of a mission to bring critical care closer to where trauma strikes—whether it’s a roadside crash, a battlefield, or a remote clinic.

The Founder’s Journey: From Personal Crisis to Public Health Solution

The story behind Miraqules is deeply personal. Founder Sabir Hossain grew up in a middle-class family in Burdwan, West Bengal. A traumatic childhood experience—watching his father bleed from an accident without access to proper first aid—left a lasting impression. Years later, while pursuing his master’s in Biomedical Engineering at NIT Rourkela, Sabir began working on biomaterials under Professor Devendra Verma. This academic pursuit soon evolved into a practical mission, culminating in the development of StopBleed.

In 2018, Sabir co-founded Miraqules with Dr. Verma and his father. Dr. Mubeen Midda, a junior doctor in Delhi at the time, was drawn into the mission after seeing the product's potential firsthand. By March 2019, he joined full-time, bringing a clinical perspective that grounded the startup’s development in real-world needs.

Addressing a Global Health Crisis

Uncontrolled bleeding is a leading cause of preventable deaths globally, surpassing diseases like HIV and malaria. In India, roughly 30% of road accident deaths result from blood loss. Existing solutions like tourniquets and pressure dressings are often inadequate or situational. Miraqules(Miracle + Molecules) aims to bridge this gap with StopBleed, a first-response hemostat that is easy to use and effective across a range of settings—from ERs and ambulances to home first-aid kits.

Inside the Technology: What Sets StopBleed Apart

Unlike conventional hemostats, StopBleed mimics the body’s natural clotting process using a nano-biopolymer that forms fibrin-like threads. It features a 30x higher absorption rate, charge-based clotting acceleration, and atraumatic removal—crucial in emergency care. Designed in multiple formats (powder, gauze, pellets, and patches), the product is adaptable to various types of bleeding injuries, offering frontline responders and clinicians a powerful new tool in trauma management.

Market Reach: From Battlefields to Backpacks

Currently, Miraqules operates on a B2B and B2G model, planning to sell StopBleed in different formats priced between ₹300 and ₹5000. The long-term goal is to make StopBleed as common in first-aid kits as bandages, enabling bystanders to act before medical help arrives.

The potential market is massive. Globally, over 700 million injuries occur annually, with more than 6 million deaths from blood loss. In India alone, 1500 road accidents happen daily. Yet hemostatic products remain scarce at the point of injury. Miraqules is looking to change that by offering a scalable, affordable solution.

Achievements, Recognition, and Funding

Over the past seven years, Miraqules has raised around $800,000 and secured patents in India, the U.S., and China. A pilot-scale manufacturing facility is in place, and the company is currently conducting human studies at St. John’s Hospital in Bangalore. Miraqules has received support from the Indian Council of Medical Research and won accolades such as the Startup MahaRathi Award and MassChallenge Israel Platinum Winner title.

Their recent partnership with the Maharashtra Government will see StopBleed deployed in trauma centers and ambulances, reaching 800 patients as part of a paid pilot.

Challenges and the Road Ahead

Manufacturing scale-up remains the company’s biggest challenge. Regulatory hurdles and limitations in current bio-incubation facilities mean Miraqules will need to either raise capital to build its own facility or find strategic manufacturing partners. The immediate focus is on completing clinical trials and securing regulatory approvals from India’s CDSCO and the U.S. FDA.

By 2026, the startup aims to ship 10,000 units, gain major public health adoption, and begin sales in the U.S. and Indian markets. Long-term goals include serving over 5 million patients and introducing 3–4 new wound care products to transform trauma and surgical care.

A Mission Beyond Medicine

Beyond saving lives, StopBleed promises to reduce hospital stays, lower transfusion rates, and ease healthcare costs—especially in resource-constrained settings. For Sabir and his team, the product isn’t just about science—it’s about giving people a fighting chance when every second counts.

“Startups are consuming,” says Sabir. “Resilience will be more important than hard work. Be obsessed with the problem.” For him, Miraqules is more than a company—it’s a purpose forged from pain and shaped by persistence.